Monoaminergic neurotransmitter systems

The monoaminergic neurotransmitter systems are a complex network of neurons in the central nervous system that utilize biogenic amines—specifically dopamine, serotonin, norepinephrine, and histamine—to modulate a vast range of physiological and behavioral processes (Wikipedia, 2024). These systems originate primarily in brainstem nuclei, such as the raphe nuclei and locus coeruleus, and project extensively throughout the cortex and limbic system to regulate mood, arousal, reward, and motor control (StatPearls, 2023). Dysregulation of monoaminergic signaling is a central feature in the pathophysiology of major psychiatric and neurological disorders, including depression, schizophrenia, and Parkinson's disease (NIH, 2021). Pharmacological interventions typically target specific molecular components within these systems, such as G protein-coupled receptors, plasma membrane transporters (e.g., SERT, DAT, NET), or metabolic enzymes like monoamine oxidase (MAO) to restore neurochemical balance (PubMed, 2022). Consequently, these systems represent a foundational framework for modern psychopharmacology and neurology, serving as the primary target for many antidepressant, antipsychotic, and stimulant medications.

Other names

Monoamine systemsBiogenic amine systemsMonoaminergic pathwaysMonoaminergic signaling

Drugs modulate these systems via reuptake inhibition (e.g., SSRIs, SNRIs), receptor agonism or antagonism (e.g., dopamine D2 antagonists), inhibition of degradative enzymes (e.g., MAOIs, COMT inhibitors), or modulation of vesicular storage (e.g., VMAT2 inhibitors).